COPD is a type of preventable and treatable progressive
lung disease that is characterised by long-term respiratory symptoms and
airflow limitation. Its main symptoms include shortness of breath and a cough,
and possible chronic sputum production. It’s a progressive disease that worsens
over time, making everyday activities such as walking or dressing more and more
difficult.
COPD continues to be a major
public health problem because of its high prevalence, raising incidence,
considerable mortality, and associated social and economic costs.
COPD has been traditionally
considered a self-inflicted disease caused by tobacco smoking and characterised
by an accelerated rate of lung function decline with age. However, about a
third of patients with COPD are never smokers and about half of patients with
COPD develop the disease without evidence of any acceleration of the
physiological rate of loss of lung function, clearly indicating that there must
be other pathogenic mechanisms to consider. In fact, a large general population
study in Austria has identified many environmental factors (including but
going beyond smoking) associated with reduced lung function in different age
bins throughout life.
COPD can no longer be considered
a “uniform” disease, so the traditional definition and classification of COPD
needs to be revisited and updated (including that of the episodes of
exacerbations of the disease). A recent paper proposes that “COPD is a
heterogeneous lung condition characterised by chronic respiratory symptoms
(dyspnea, cough, expectoration) due to persistent abnormalities of the airways
(bronchitis, bronchiolitis), and/or alveoli (emphysema) that cause persistent,
often progressive, airflow limitation”. It also recognises that there are
different “types” of COPD according to the cause, including genetic COPD, COPD
due to abnormal lung development, environmental COPD (which includes cigarette
smoking), COPD and biomass and pollution exposure, COPD due to infections, COPD
and asthma, COPD of unknown cause, and COPD of mixed causes. So far, research
has focused almost exclusively on COPD-cigarette smoking. It is necessary to
consider these different forms of COPD to investigate their natural history and
optimal treatment. In this setting, a management strategy based on so-called
treatable traits (TTs) seems advisable. This is a precision medicine strategy,
which is agnostic (i.e. independent) of the traditional clinical diagnosis (COPD,
asthma, and asthma-COPD overlap) and based on the identification of TTs in each
individual patient. TTs can be identified based on “phenotypic” (i.e., clinical)
recognition and/or on a deep understanding of critical causal pathways
(“endotypes”) through validated “biomarkers”.
Finally, it is now accepted that COPD can occur in young subjects (<50 yr of age) and
that some individuals may have (at any age) structural (e.g. emphysema) and/or
functional lung abnormalities (e.g., low carbon monoxide diffusing capacity) in
the absence of airflow limitation (Pre-COPD) that may progress to COPD or not.
Based on article: Am J Physiol Lung Cell Mol Physiol323: L615–L618, 2022
For more information contact Grupo HPA Saude on +351 282 420 400